
|Videos|July 25, 2017
Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.
The next steps for immunotherapy in this disease is moving it earlier in the course of treatment, says Bauml.
For example, neoadjuvant pembrolizumab (Keytruda) showed major pathologic responses after a single dose in patients with resectable tumors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5




































